Doximity vs Waystar
DOCS and WAY side by side, both in computer programming, data processing, and other computer related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DOCS and WAY compare
Doximity and Waystar are about the same size, with market caps of $5.9B and $5.5B.
On earnings, Waystar is cheaper: it trades at 41.8× trailing earnings, against 46.1× for Doximity.
Waystar grew revenue faster over the last twelve months (21.4% versus 6.5% for Doximity).
Doximity keeps more of each dollar of sales as profit, with a net margin of 21.1% compared with 10.7% at Waystar.
Doximity scores higher on the StockData Score (15 against 13 for Waystar), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DOCS | WAY |
|---|---|---|
| Size and price | ||
| Market cap | $5.9B | $5.5B |
| Share price | $33.22 | $28.84 |
| Change, 1 year | −36.8% | −20.1% |
| Change, 5 years | −45.7% | – |
| Beta (5Y) | 1.66 | 0.94 |
| Employees | 880 | 340 |
| StockData Score | ||
| Total score | 15 (better) | 13 |
| Valuation score | 2 | 3 (better) |
| Growth score | 3 | 4 (better) |
| Performance score | 4 (better) | 3 |
| Health score | 6 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 46.1× | 41.8× (better) |
| P/S | 9.0× | 4.4× (better) |
| P/B | 6.4× | 1.4× (better) |
| EV/EBITDA | 29.8× | 15.2× (better) |
| P/FCF | – | 20.9× |
| PEG | 2.03 | – |
| FCF yield | – | 4.8% |
| Fair value | $27.20 | $31.26 |
| Margin of safety | −22.1% | 7.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 6.5% | 21.4% (better) |
| Revenue growth, 5Y average | 25.5% | – |
| Net income growth (TTM) | −44.8% | 21.6% (better) |
| EPS growth (TTM) | −42.9% | 11.3% (better) |
| EPS growth, 5Y average | 33.6% | – |
| Profitability | ||
| Gross margin | 86.8% (better) | 69.4% |
| Operating margin | 26.3% (better) | 21.9% |
| Net margin | 21.1% (better) | 10.7% |
| FCF margin | – | 20.9% |
| Return on equity | 13.8% (better) | 3.7% |
| Return on invested capital | 14.6% (better) | 4.2% |
| Financial health | ||
| Debt / equity | 0.00 | 0.36 (better) |
| Net debt / EBITDA | – | 2.69 |
| Current ratio | 6.37 (better) | 2.10 |
| Altman Z-score | 23.57 (better) | 2.18 |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | 7.3% | – |
| Shareholder yield | 7.3% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 71.6% | 110% |
| Held by insiders | 33.6% | 63.5% |
| Insider net buying, 12 months | −$2.0M (better) | −$12.0M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 5.9% | 21.5% |
Go deeper
- DOCS stock overview
- DOCS income statement
- DOCS valuation and score
- WAY stock overview
- WAY income statement
- WAY valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.